HighVista Strategies’s Stoke Therapeutics STOK Stock Holding History

HighVista Strategies’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.04M	Sell	62,617 -52,922	-46%	-$1.74M	0.56%	59
2025 Q4	$3.67M	Buy	+115,539	New	+$3.47M	0.94%	35
2021 Q4	–	Sell	-47,594	Closed	-$1.21M	–	113
2021 Q3	$1.21M	Buy	+47,594	New	+$1.33M	0.8%	36
2021 Q2	–	Sell	-13,692	Closed	-$532K	–	140
2021 Q1	$532K	Sell	13,692 -3,976	-23%	-$226K	0.4%	67
2020 Q4	$1.09M	Buy	17,668 +586	+3%	+$26.9K	0.7%	23
2020 Q3	$572K	Sell	17,082 -652	-4%	-$18.6K	0.42%	30
2020 Q2	$423K	Buy	+17,734	New	+$421K	0.35%	48

Other funds holding STOK

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

HighVista Strategies's STOK Position: Q1 2026 in Review

HighVista Strategies reduced its Stoke Therapeutics (STOK) stake by 46% in Q1 2026, selling an estimated $1.74M and leaving 62,617 shares worth $2.04M. The position accounts for 0.56% of the portfolio, ranked #59.

HighVista Strategies first reported a position in STOK in Q2 2020 and has held it in 7 quarters since. The position peaked at $3.67M in Q4 2025. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

HighVista Strategies held 62,617 shares of Stoke Therapeutics worth $2.04M as of Q1 2026.
HighVista Strategies sold 52,922 Stoke Therapeutics shares in Q1 2026, an estimated $1.74M.
Stoke Therapeutics made up 0.56% of HighVista Strategies's portfolio in Q1 2026, its #59 holding.
HighVista Strategies first reported a position in Stoke Therapeutics in Q2 2020 and has held it in 7 quarters since.
HighVista Strategies's Stoke Therapeutics position peaked at $3.67M in Q4 2025.
196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.